189 related articles for article (PubMed ID: 28812434)
1. [pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells.
Booth L; Roberts JL; Poklepovic A; Dent P
Cancer Biol Ther; 2017 Sep; 18(9):705-714. PubMed ID: 28812434
[TBL] [Abstract][Full Text] [Related]
2. PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].
Booth L; Roberts JL; Poklepovic A; Dent P
Oncotarget; 2017 Feb; 8(8):13464-13475. PubMed ID: 28088782
[TBL] [Abstract][Full Text] [Related]
3. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide.
Booth L; Roberts JL; Poklepovic A; Gordon S; Dent P
Oncotarget; 2017 Jan; 8(1):1449-1468. PubMed ID: 27903966
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitors enhance the immunotherapy response of melanoma cells.
Booth L; Roberts JL; Poklepovic A; Kirkwood J; Dent P
Oncotarget; 2017 Oct; 8(47):83155-83170. PubMed ID: 29137331
[TBL] [Abstract][Full Text] [Related]
5. Neratinib augments the lethality of [regorafenib + sildenafil].
Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Hancock JF; Poklepovic A; Dent P
J Cell Physiol; 2019 Apr; 234(4):4874-4887. PubMed ID: 30203445
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
Del Bufalo D; Desideri M; De Luca T; Di Martile M; Gabellini C; Monica V; Busso S; Eramo A; De Maria R; Milella M; Trisciuoglio D
Mol Cancer; 2014 Oct; 13():230. PubMed ID: 25301686
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells.
Hwang KE; Kim YS; Jung JW; Kwon SJ; Park DS; Cha BK; Oh SH; Yoon KH; Jeong ET; Kim HR
Oncotarget; 2015 Oct; 6(30):29482-96. PubMed ID: 26334320
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.
Booth L; Roberts JL; Spiegel S; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):597-607. PubMed ID: 30388910
[TBL] [Abstract][Full Text] [Related]
9. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
[TBL] [Abstract][Full Text] [Related]
10. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
[TBL] [Abstract][Full Text] [Related]
11. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells.
Okimoto T; Kotani H; Iida Y; Koyanagi A; Tanino R; Tsubata Y; Isobe T; Harada M
Cancer Sci; 2020 Jun; 111(6):1910-1920. PubMed ID: 32232903
[TBL] [Abstract][Full Text] [Related]
13. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.
Zheng H; Zhao W; Yan C; Watson CC; Massengill M; Xie M; Massengill C; Noyes DR; Martinez GV; Afzal R; Chen Z; Ren X; Antonia SJ; Haura EB; Ruffell B; Beg AA
Clin Cancer Res; 2016 Aug; 22(16):4119-32. PubMed ID: 26964571
[TBL] [Abstract][Full Text] [Related]
14. GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy.
Booth L; Roberts JL; West C; Von Hoff D; Dent P
J Cell Physiol; 2020 Nov; 235(11):8098-8113. PubMed ID: 31951027
[TBL] [Abstract][Full Text] [Related]
15. (Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo.
Dent P; Booth L; Roberts JL; Poklepovic A; Hancock JF
J Cell Physiol; 2020 Oct; 235(10):6862-6874. PubMed ID: 31985048
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies.
Dent P; Booth L; Poklepovic A
Immunometabolism; 2020; 2(1):. PubMed ID: 31885880
[TBL] [Abstract][Full Text] [Related]
17. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
Booth L; Roberts JL; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(1):109-121. PubMed ID: 30142009
[TBL] [Abstract][Full Text] [Related]
18. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
Pang L; Han S; Jiao Y; Jiang S; He X; Li P
Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
[TBL] [Abstract][Full Text] [Related]
19.
Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G
Front Immunol; 2019; 10():454. PubMed ID: 30967859
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]